Press release
Irritable Bowel Syndrome Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Tryp Therapeutics, CinRx Pharma, Otsuka Pharmaceutical, RaQualia Pharma, Biomi
Irritable Bowel Syndrome Clinical Trials
According to DelveInsight, the Irritable Bowel Syndrome (IBS) pipeline comprises 15+ key companies actively developing 20+ treatment therapies for the condition.
Irritable Bowel Syndrome Overview:
Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits, which can manifest as diarrhea, constipation, or a mix of both. The underlying cause remains uncertain but is believed to stem from a combination of abnormal gut motility, visceral hypersensitivity, gut-brain axis dysfunction, and microbiome imbalances. Common triggers include specific foods, stress, and hormonal changes. While there is no definitive cure, symptom management involves dietary adjustments, pharmacological therapies, and lifestyle modifications.
Clinically, IBS presents with recurrent abdominal pain associated with bloating and stool irregularities. Patients may report excessive gas, mucus in stools, and a sensation of incomplete bowel emptying. The severity and frequency of symptoms vary, often fluctuating in response to stress or dietary factors.
Diagnosis primarily relies on clinical criteria, as there are no specific diagnostic tests for IBS. The Rome IV criteria are commonly used, requiring abdominal pain at least one day per week over the past three months, linked to changes in bowel movement frequency, stool form, or pain related to defecation. To rule out other gastrointestinal disorders-such as celiac disease or inflammatory bowel disease (IBD)-clinicians may employ blood tests, stool studies, or colonoscopy.
Request for a detailed insights report on Irritable Bowel Syndrome pipeline insights [https://www.delveinsight.com/report-store/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
DelveInsight's "Irritable Bowel Syndrome Pipeline Insight 2025" report offers an in-depth evaluation of the ongoing clinical research and future growth opportunities within the Irritable Bowel Syndrome (IBS) therapeutics market.
Key Takeaways from the Irritable Bowel Syndrome Pipeline Report
*
DelveInsight's Irritable Bowel Syndrome pipeline report highlights a dynamic landscape with over 15 active companies developing more than 20 therapeutic candidates for IBS management.
*
In January 2025, the FDA granted tentative approval to Amneal Pharmaceuticals' generic rifaximin 550 mg for diarrhea-predominant IBS (IBS-D), with final approval pending resolution of ongoing patent litigation with Bausch Health.
*
Leading companies such as Tryp Therapeutics, CinRx Pharma, Otsuka Pharmaceutical, RaQualia Pharma, Biomica, and Octavian Therapeutics are advancing innovative treatment options to enhance the IBS therapeutic space.
*
Notable pipeline candidates in various stages of development include CIN-103, RQ-00310941, OCT-461201, BMC426, and others.
Irritable Bowel Syndrome Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Irritable Bowel Syndrome Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Irritable Bowel Syndrome treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Irritable Bowel Syndrome market.
Download our free sample page report on Irritable Bowel Syndrome pipeline insights [https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Irritable Bowel Syndrome Emerging Drugs
CIN-103 - CinRx Pharma
CIN-103 is a novel formulation of phloroglucinol, a non-opioid small molecule already approved in several countries for treating gastrointestinal conditions. Developed for long-term use, CinRx has incorporated both immediate- and delayed-release technologies to create a proprietary pulsatile delivery system that ensures sustained drug exposure with reduced dosing frequency. The therapy targets multiple underlying mechanisms of diarrhea-predominant irritable bowel syndrome (IBS-D), including abnormal motility, secretion, pain, spasms, and inflammation. CIN-103 is currently being evaluated in Phase II clinical trials for IBS.
RQ-00310941 - RaQualia Pharma
RQ-00310941 is an innovative 5-HT2B receptor antagonist developed by RaQualia Pharma for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). The 5-HT2B receptor, a subtype of serotonin receptors, is crucial in controlling gastrointestinal motility. By inhibiting this receptor, the drug is designed to alleviate visceral hypersensitivity and restore normal bowel function in IBS patients. RQ-00310941 is currently undergoing Phase I clinical evaluation for IBS.
Irritable Bowel Syndrome Companies
More than 15 companies are actively engaged in developing treatments for Irritable Bowel Syndrome (IBS). Among these, CinRx Pharma's drug candidate has reached the most advanced stage of development, currently in Phase II clinical trials.
Request the Sample PDF to Get Detailed Insights About the Irritable Bowel Syndrome Pipeline Reports Offerings [https://www.delveinsight.com/report-store/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
DelveInsight's report covers around 75+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Irritable Bowel Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Irritable Bowel Syndrome Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Irritable Bowel Syndrome Therapies and Key Companies: Irritable Bowel Syndrome Clinical Trials and advancements [https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Irritable Bowel Syndrome Pipeline Therapeutic Assessment
- Irritable Bowel Syndrome Assessment by Product Type
- Irritable Bowel Syndrome By Stage
- Irritable Bowel Syndrome Assessment by Route of Administration
- Irritable Bowel Syndrome Assessment by Molecule Type
Download Irritable Bowel Syndrome Sample report to know in detail about the Irritable Bowel Syndrome treatment market @ Irritable Bowel Syndrome Therapeutic Assessment [https://www.delveinsight.com/report-store/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=irritable-bowel-syndrome-clinical-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-tryp-therapeutics-cinrx-pharma-otsuka-pharmaceutical-raqualia-pharma-biomi]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Irritable Bowel Syndrome Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Tryp Therapeutics, CinRx Pharma, Otsuka Pharmaceutical, RaQualia Pharma, Biomi here
News-ID: 4251701 • Views: …
More Releases from ABNewswire
DDC Enterprise Limited Is Showing What a Modern Consumer Company Looks Like
Every era forces consumer companies to adapt to the pressures of the time. A generation ago, the biggest challenge was scale. Then it became brand power. Then e-commerce. Today's environment looks different. Markets move faster. Supply chains feel less predictable. Input costs swing. Currency shifts can reshape entire quarters. Any company operating in this landscape is under pressure to rethink what stability even means.
DDC Enterprise Limited (NASDAQ: DDC) is one…
Melbourne Buyers Agent Ni Advocacy Redefines Luxury Property Acquisition by Inte …
Ni Advocacy transforms Melbourne property buying by integrating expert advocacy with certified valuation. Founder Kevin Ni leverages data-driven insights to protect clients from overpaying for luxury homes and investments. Specializing in off-market access for budgets over $3M, the firm provides a strategic advantage for investors and homebuyers seeking the best buyers agent in Melbourne.
MELBOURNE, Australia - In a property market frequently characterized by emotional bidding and opaque pricing strategies, Ni…
Three-Time Award Winner She She's Closet Transforms Holiday Shopping with Person …
She She's Closet introduces exclusive holiday personal styling sessions to help busy professional women find perfect statement pieces for seasonal events. The Miramar boutique's unique approach combines global artisan craftsmanship with tailored customer care, revolutionizing the holiday shopping experience for discerning customers.
She She's Closet, the acclaimed Miramar boutique that has dominated local retail awards for three consecutive years, is revolutionizing the holiday shopping experience with an enhanced focus on personalized…
How The Moss Way Is Redefining Quality with Hand-Harvested Irish Sea Moss
In an era where wellness claims often outpace scientific backing, one British brand is charting a different course. The Moss Way, a pioneering natural health company, is challenging the status quo of the superfood industry by delivering what many consider the purest, most potent Irish Sea Moss available in the UK market today.
London, United Kingdom - November 25, 2025 - In an era where wellness claims often outpace scientific backing,…
More Releases for Irritable
Irritable Bowel Syndrome Medication Market Massive Growth opportunity Ahead
Exactitude Consultancy., Ltd. announces the release of the report "Global Irritable Bowel Syndrome Medication Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets.…
Irritable Bowel Syndrome Treatment Market | $2 Billion by 2026
The market for treating irritable bowel syndrome (IBS) has witnessed significant growth in recent years. In 2018, the estimated value of the IBS treatment market was $1,071 million. However, with increasing awareness and advancements in medical research, the market is projected to reach a staggering $2,012 million by 2026. This represents a remarkable compound annual growth rate (CAGR) of 8.2% during the forecast period from 2019 to 2026.
Irritable bowel syndrome…
Irritable Bowel Syndrome Treatment Market - Industry Trends and Forecast to 2028
The Global Irritable Bowel Syndrome Treatment Market Growth at a rate of 9.32% in the forecast period 2022 to 2028
Global Irritable Bowel Syndrome Treatment Market Size
Irritable bowel syndrome treatment market is segmented on the basis of type, product and end use. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them…
Global Irritable Bowel Syndrome Treatment Market Strategical Analysis Report 202 …
The primary purpose of the statistical analysis is to use data analysis and descriptive statistics. It helps to summarize data from a sample using indexes like mean or standard deviation and inferential statistics. This report includes information and statistics on price levels, location of the product, and demand for the product. The best thing about the statistical analysis report is that it allows businesses to make decisions in terms of…
Irritable Bowel Syndrome (IBS) Treatment Market: Increasing Prevalence of Irrita …
The major factors such as the increasing prevalence of irritable bowel syndrome diseases and rising research & development activities drive the market growth. However, the limited number of product availability and treatment inefficiency restrain the market growth. IBS is a common chronic condition that affects the abdominal organ, large intestine. It is also known as spastic colon, mucous colitis, irritable colon, and spastic colitis. The condition is much different than…
Ayurvedic Cure For Irritable Bowel Syndrome (IBS) Without Operation
The Grocare is a leading natural solution provider for chronic lifestyle diseases – Irritable bowel syndrome (IBS), is a gift of enterprise, and commitment to quality and modern-day buyers’ changing needs. Grocare conforms to stringent quality-related compliances and cost-efficient processes in all aspects of formulation and production. At Grocare, we use natural ingredients developed over the years of research and development. It is FDA certified, safe to use, and affordable…
